Medicines | Horizonscan geneesmiddelen

Lisdexamfetamine ^IND Melatonine Molindone

Blinatumomab ^IND

Dasatinib

Geïndiceerd voor de behandeling van volwassen patiënten met: nieuw gediagnosticeerde Philadelphiachromosoom-positieve (Ph+) chronische myeloïde leukemie (CML) in de chronische fase. CML in de chronische, acceleratie- of blastaire fase, die resistent of intolerant zijn voor eerder toegediende geneesmiddelen inclusief imatinib. Ph+ acute lymfoblastaire leukemie (ALL) en lymfoïde blasten CML die resistent of intolerant zijn voor eerder toegediende geneesmiddelen. Ook geïndiceerd voor de behandeling van pediatrische patiënten met: nieuw gediagnosticeerde Ph+ CML in de chronische fase (Ph+ CML-CP) of met Ph+ CML-CP die resistent of intolerant zijn voor eerder toegediende geneesmiddelen waaronder imatinib. Nieuw gediagnosticeerde Ph+ ALL in combinatie met chemotherapie. ^G Geïndiceerd voor de behandeling van volwassen patiënten met: nieuw gediagnosticeerde Philadelphiachromosoom-positieve (Ph+) chronische myeloïde leukemie (CML) in de chronische fase. CML in de chronische, acceleratie- of blastaire fase, die resistent of intolerant zijn voor eerder toegediende geneesmiddelen inclusief imatinib. Ph+ acute lymfoblastaire leukemie (ALL) en lymfoïde blasten CML die resistent of intolerant zijn voor eerder toegediende geneesmiddelen. Ook geïndiceerd voor de behandeling van pediatrische patiënten met: nieuw gediagnosticeerde Ph+ CML in de chronische fase (Ph+ CML-CP) of met Ph+ CML-CP die resistent of intolerant zijn voor eerder toegediende geneesmiddelen waaronder imatinib. Nieuw gediagnosticeerde Ph+ ALL in combinatie met chemotherapie. ^G

autologous anti-CD19-transduced CD3+ cells ^IND

Arimoclomol ^IND

Azacitidine Eprenetapopt Glasdegib Idasanutlin Imetelstat Iomab-B Pevonedistat Sapacitabine Venetoclax ^IND

Axicabtagene ciloleucel ^IND Crizotinib ^IND Ibrutinib ^IND Lisocabtagene maraleucel Pirtobrutinib Tafasitamab Tagraxofusp Zamtocabtagene autoleucel Zanubrutinib ^IND loncastuximab tesirine

Dabigatran ^G Dabigatran etexilate ^IND Ravulizumab ^IND

Budesonide / formoterol ^IND Dupilumab ^IND Masitinib Tezepelumab

Bedaquiline ^IND Ceftobiprole Ceftolozane / tazobactam ^IND Citric acid / lactic acid / potassium bitartrate ^IND Clindamycin Delafloxacin ^IND

Delamanid

Deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adults, adolescents and children with a body weight of at least 30kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. ^IND Deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adults, adolescents, and children and infants with a body weight of at least 10kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. ^IND

Eravacycline

Imipenem / cilastatin / relebactam

Recarbrio is indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options. Treatment of hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), in adults. Treatment of bacteraemia that occurs in association with, or is suspected to be associated with HAP or VAP, in adults. ^IND

Ozenoxacine SER 109 Tebipenem

Avelumab ^IND Durvalumab ^IND Enfortumab vedotin Nivolumab ^IND Oportuzumab monatox

Etrolizumab ^IND Filgotinib ^IND Mirikizumab Ozanimod ^IND Risankizumab ^IND Tenapanor Upadacitinib ^IND Vedolizumab ^IND

Autologous glioma tumor cell lysates Vocimagene amiretrorepvec

Abemaciclib ^IND

Atezolizumab

Extension of indication to include Tecentriq in combination with nab-paclitaxel and anthracycline-based chemotherapy for the neoadjuvant treatment of adult patients with locally advanced or early Triple Negative Breast Cancer (TNBC). ^IND 1L advanced or mTNBC +cobimetinib+(nab)paclitaxel ^IND

Balixafortide Efbemalenograstim alfa Margetuximab Neratinib ^IND Olaparib ^IND Paclitaxel

Pembrolizumab

Extension of indication for Keytruda to include in combination with chemotherapy, treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express PD L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease. ^IND Extension of indication for Keytruda in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery of adults with locally advanced, inflammatory, or earlystage triple-negative breast cancer at high-risk of recurrence. ^IND

Pertuzumab / trastuzumab Sacituzumab govitecan Tesetaxel

Trastuzumab deruxtecan

Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti HER2 based regimens. Patients with HER2 low, unresectable, and/or metastatic breast cancer previously treated with 1-2 prior lines of chemotherapy in the metastatic setting and has progressed on, and would no longer benefit from, endocrine therapy. ^IND Treatment of adult patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane 2L. ^IND

Trastuzumab duocarmazine Tucatinib

Acalabrutinib

Calquence as monotherapy is indicated for the treatment of adult patients with relapsed/refractory CLL (chronic lymphocytic leukemia). Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).

Duvelisib

Ibrutinib

Extension of indication to the existing chronic lymphocytic leukaemia (CLL) indication to include combination use with obinutuzumab for the treatment of adult patients with previously untreated CLL. ^IND Extension of indication in chronic lymphocytic leukaemia (CLL) to add combination with rituximab as follows; Ibrutinib in combination with rituximab or obinutuzumab for the treatment of adult patients with previously untreated CLL (Young and Fit). ^IND

Moxetumomab pasudotox Ublituximab Zanubrutinib ^IND ibrutinib ^IND

Asciminib

Beclometason/formoterol/glycopyrronium

APN01 Anakinra ^IND Bamlanivimab/ etesevimab Baricitinib ^IND Casirivimab/imdevimab Dapagliflozine ^IND Molnupiravir PF-07321332 / ritonavir Regdanvimab ^IND Remdesivir ^IND Sotrovimab Tocilizumab ^IND

Avacopan

Cemiplimab ^IND Lifileucel

Eflornithine / sulindac Nivolumab ^IND Tegafur / gimeracil / oteracil ^IND

Elexacaftor / tezacaftor / ivacaftor

Kaftrio is indicated in a combination regimen with ivacaftor 150mg tablets for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene

Ivacaftor ^IND Tezacaftor / ivacaftor ^IND

Aducanumab

Bupropion/dextromethorphan

Esketamine

Spravato, in combination with a SSRI or SNRI, is indicated for adults with treatment-resistant major depressive disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode. Extension of indication to include a new indication for SPRAVATO® (esketamine nasal spray) co-administered with oral antidepressant therapy in adults with a moderate to severe episode of Major Depressive Disorder (MDD), as acute short term treatment, for the rapid reduction of depressive symptoms, which according to clinical judgement constitute a psychiatric emergency. ^IND

Zuranolone

Bexagliflozine Dapagliflozine ^IND Dasiglucagon

Exenatide

Diabetes type 2 Extension of indication to include the treatment of type 2 diabetes in adolescents and children aged 10 years and above ^IND

Finerenon Polyethylene glycol loxenatide Reparixin Sotagliflozine ^IND Teplizumab Tirzepatide

Golodirsen

Brivaracetam ^IND Cannabidiol ^IND Cenobamate

Fenfluramine

Fintepla is indicated for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older. Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome ^IND

Ganaxolone Lacosamide ^IND

Aflibercept ^IND Avacincaptad pegol Bevacizumab-vikg Brolucizumab ^IND Faricimab Lenadogene nolparvovec Netarsudil / latanoprost Perfluorohexyloctane Phentolamine

Ranibizumab

Wet age-related macular degeneration (AMD). ^BS Wet age-related macular degeneration (AMD). ^BS Wet age-related macular degeneration (AMD). ^BS Wet age-related macular degeneration (AMD). ^BS Treatment of neovascular age-related macular degeneration (AMD)

Reproxalap Sepofarsen Timrepigene emparvovec

Ibrexafungerp ^IND Oteseconazole

Posaconazol

Extension of indication to include primary treatment of invasive aspergillosis in adults and adolescents from 13 years of age for Noxafil gastroresistant tablet and concentrate for solution for infusion. ^IND Extension of indication to include primary treatment of invasive aspergillosis in paediatric patients from 2 years of age weighing more than 40kg and adults for Noxafil gastroresistant tablet and concentrate for solution for infusion. Noxafil gastro-resistant tablets and solution are indicated for use in the treatment of the following fungal infections: Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products. ^IND

Rezafungin

Atazanavir / cobicistat Cabotegravir Fostemsavir Lenacapavir

Leukocyte interleukin Pembrolizumab ^IND

Atogepant Dihydroergotamine Eptinezumab Erenumab Fremanezumab Galcanezumab Lasmiditan Meloxicam / rizatriptan Rimegepant

Eptacog alfa (activated) ^BS Eptacog beta (activated) Etranacogene dezaparvovec FLT180a Fibrinogen Valoctocogene roxaparvovec

Axicabtagene ciloleucel ^IND Copanlisib Hypericin Lacutamab Mosunetuzumab Umbralisib

Fluticasone propionate Tixagevimab / cilgavimab

Avelumab ^IND Cabozantinib ^IND Lenvatinib ^IND

Pembrolizumab

Adjuvant treatment in monotherapy of adults with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ^IND Extension of indication for Keytruda to include in combination with lenvatinib first line treatment of adults with advanced renal cell carcinoma (RCC). ^IND

Tivozanib ^IND

Bempedoic acid Bempedoic acid / ezetimibe Evinacumab Evolocumab ^IND Inclisiran

Durvalumab

Durvalumab (+/- bevacizumab) in combinatie met TACE in patiënten met locoregionale HCC. ^IND In combination with tremelimumab in patients with HCC not eligible for locoregional therapy (1L). ^IND

Lenvatinib ^IND Pembrolizumab ^IND Pemigatinib Tremelimumab

Cenicriviroc Givosiran

Maralixibat

Progressive Familial Intrahepatic Cholestasis Type 2 Treatment of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment of cholestatic liver disease in patients with Alagille syndrome (ALGS) 1 year of age and older. ^IND

Obeticholic acid Odevixibat Seladelpar

Amivantamab

Atezolizumab

Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC. ^IND Extension of indication to include adjuvant treatment of non-small cell lung cancer (NSCLC) following resection and platinum-based chemotherapy for adult patients whose tumours have PD-L1 expression on ≥ 1% of tumour cells (TC). ^IND

Avelumab ^IND Capmatinib

Cemiplimab

Libtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC. ^IND Cemiplimab wordt onderzocht als eerstelijns behandeling in combinatie met chemotherapie voor volwassen patiënten met lokaal gevorderd of gemetastaseerde plaveiselcel en niet-plaveiselcel NSCLC (stadium IIIB/C-IV) onafhankelijk van PD-L1 expressie. ^IND

Durvalumab

Non-small cell lung cancer (NSCLC) stage IV, in combination with tremelimumab and chemo,1L. ^IND Non-small cell lung cancer (NSCLC) stage IV, in combination with chemo, 1L. ^IND Imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). ^IND 1L advanced NSCLC ^IND Completely resected NSCLC ^IND Lokaal gevorderd, niet-resectabel NSCLC (stadium III) ^IND

Ensartinib Entrectinib Lorlatinib ^IND Lurbinectedin Mobocertinib Nivolumab ^IND OSE-2101 Osimertinib ^IND Pralsetinib Selpercatinib Sotorasib Tepotinib Trastuzumab deruxtecan ^IND Trilaciclib pembrolizumab ^IND

Ambrisentan ^IND Benralizumab ^IND Gefapixant

Mepolizumab

Extension of indication to include Eosinophilic Granulomatosis with Polyangiitis (EGPA) to Nucala ^IND Extension of indication to include Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) for Nucala (mepolizumab). ^IND

Pirfenidone ^IND

Pirfenidone ^G

Nivolumab ^IND

Arimoclomol Autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A gene Avalglucosidase alfa Bardoxolone Methyl Betaine ^G Cipaglucosidase alfa / Miglustat Elamipretide Elivaldogene autotemcel Fexapotide Fosdenopterin Hydrocortison Kaliumcitraat / kaliumwaterstofcarbonaat Leriglitazone Levoketoconazole Liraglutide ^IND Lonafarnib Migalastat ^IND Octreotide Olenasufligene relduparvovec Olipudase alfa Palovarotene Pegunigalsidase alfa Pegvaliase Reloxaliase Sapropterin ^G Somatrogon Sparsentan Tenapanor ^IND Trientine Triheptanoin Veverimer

Belantamab mafodotin

Blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. Multiple Myeloma 3L ^IND

Carfilzomib ^IND Ciltacabtagene autoleucel

Daratumumab

Extension of indication to extend the existing therapeutic indication for daratumumab in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT). ^IND Extension of indication to extend the existing therapeutic indication for daratumumab in combination with lenalidomide and dexamethasone (Rd) for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). ^IND Darzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (AL) amyloidosis. ^IND In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy. ^IND Multipel myeloom frontline behandeling in combinatie met VRd voor patiënten die niet in aanmerking komen voor een ASCT. ^IND

Idecabtagene vicleucel

Isatuximab

Sarclisa is indicated in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. ^IND In Combination With Bortezomib, Lenalidomide and Dexamethasone (Isa VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant. ^IND

Lenalidomide ^IND Melphalan flufenamide ^IND Pomalidomide ^IND

Selinexor

Nexpovio is indicated in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. Extension of indication for Nexpovio in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. ^IND

Thalidomide ^G Zevorcabtagene autoleucel

Dimethyl fumarate

Extension of indication to include treatment of relapsing remitting multiple sclerosis (RRMS) in paediatrics patients from 10 years of age and over. ^IND Volwassenen met 'relapsing remitting' multipele sclerose (RRMS). ^G Volwassenen met 'relapsing remitting' multipele sclerose (RRMS). ^G Volwassenen met 'relapsing remitting' multipele sclerose (RRMS). ^G

Diroximel fumarate Natalizumab Ofatumumab Ponesimod

Teriflunomide

Aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis. ^IND Volwassenen met 'relapsing remitting' multipele sclerose (RRMS). ^G

Ublituximab

AMDC-USR Amifampridine ^G Bidridistrogene xeboparvovec Sugammadex ^G

Fedratinib Momelotinib Ropeginterferon alfa-2b

Selumetinib Surufatinib

Cannabidiol gel/intradermaal Eladocagene exuparvovec Inebilizumab Remimazolam Rozanolixizumab Satralizumab Tiratricol Vutrisiran

131I-omburtamab Dostarlimab Durvalumab ^IND Entrectinib Futibatinib Glucarpidase Ivosidenib ^IND Larotrectinib

Lenvatinib

Extension of indication to include lenvatinib in combination with pembrolizumab for the treatment of adult patients with advanced endometrial carcinoma (EC) who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation ^IND Advanced or Recurrent Endometrial Cancer (1L) in combination with pembrolizumab ^IND

Lipegfilgrastim ^IND NY-ESO-1 autologous engineered TCR-T cells

Nivolumab

Opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. ^IND Opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy ^IND Extension of indication to include in combination with fluoropyrimidineand platinum-based combination chemotherapy the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) for OPDIVO. ^IND

Pembrolizumab

Extension of indication to include a new indication for Keytruda, in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in adults. ^IND Extension of indication to include pembrolizumab in combination with lenvatinib for the treatment of advanced endometrial carcinoma in adults who have disease progression following prior systemic therapy in any setting and who are not candidates for curative surgery or radiation. ^IND Keytruda, in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults whose tumours express PD‑L1 with a CPS ≥ 10. ^IND Extension of indication for Keytruda as monotherapy in the treatment of unresectable or metastatic MSI-H or dMMR colorectal, endometrial, gastric, small intestine, biliary, or pancreatic cancer in adults who have received prior therapy. ^IND

Retifanlimab Selinexor ^IND Sodium thiosulfate Tebentafusp

Adrenaline Arachis hypogaea (pinda) allergenen (capsule) Arachis hypogaea (pinda) allergenen (pleister)

Baricitinib

Systemic lupus erythematosus ^IND Extension of indication to include treatment of severe alopecia areata in adult patients for Olumiant. ^IND

Belatacept ^IND Belimumab ^IND Berotralstat Budesonide modified released capsule ^IND Canakinumab ^IND Icatibant ^G Imlifidase MDR-101 Mavorixafor RP-L201 Sutimlimab Teprotumumab Voclosporin

Zanubrutinib

Allogenic immunomodulatory progenitor cells Angiotensin II Apabetalon Dapagliflozine ^IND Emiplacel

Empagliflozine

Chronic Heart Failure With Preserved Ejection Fraction (HFpEF, LVEF >40%). ^IND Jardiance is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. ^IND

Etripamil Icosapent ethyl Macitentan ^IND Macitentan / tadalafil Mavacamten Omecamtiv mecarbil Rexlemestrocel-L Rilonacept Sotagliflozine ^IND Tafamidis ^IND Udenafil Vericiguat

Burosumab ^IND Corifollitropin alfa ^IND Dapagliflozine ^IND Diazoxide choline (controlled-release tablet) Drospirenon / estetrol, monohydraat Empagliflozine ^IND Levonorgestrel ^G Linzagolix Lonapegsomatropin Lumasiran Osilodrostat Ospemifene Relugolix ^IND Relugolix / estradiol / norethisteronen Semaglutide ^IND

Setmelanotide

Imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above. Treatment of obesity and the control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS). ^IND

Sofpironium bromide Somapacitan Spheroids of human autologous matrix-associated chondrocytes ^IND Vosoritide

Avatrombopag

Betibeglogene autotemcel

Zynteglo is geïndiceerd voor gebruik bij patiënten in de leeftijd van 12 jaar en ouder met transfusie-afhankelijke β-thalassemie (transfusion-dependent β-thalassaemia - TDT) die geen β0/β0-genotype hebben, voor wie transplantatie van hematopoëtische stamcellen (HSC) gepast is, maar geen humaan leukocytenantigeen (HLA)-compatibele gerelateerde HSC-donor beschikbaar is. Behandeling van patiënten jonger dan 12 jaar met transfusie-afhankelijke β-thalassemie (TDT) die geen β0/β0-genotype hebben en voor wie hematopoïetische stamceltransplantatie (HSC) gepast is, maar voor wie geen humaan leukocyt antigeen (HLA)-compatibele verwante HSC-donor beschikbaar is. ^IND Behandeling van patiënten met transfusie-afhankelijke β-thalassemie (TDT) die een β0 mutatie op beide allelen van het β-globuline (HBB) hebben en voor wie hematopoïetische stamceltransplantatie (HSC) gepast is, maar voor wie geen humaan leukocyt antigeen (HLA)-compatibele verwante HSC-donor beschikbaar is ^IND

Crizanlizumab Daprodustat Efgartigimod Eptacog alfa (activated) ^IND Horse anti-human T lymphocyte immunoglobulin Hydroxycarbamide ^IND Luspatercept ^IND Mepolizumab ^IND Mitapivat Pegcetacoplan RP-L102

Ravulizumab

Treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) in patients with haemolysis with clinical symptom(s) indicative of high disease activity and in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. Extension of indication to include treatment of paediatric patients with paroxysmal nocturnal haemoglobinuria (PNH) for Ultomiris (>10 kg). ^IND

Roxadustat UM171 Vadadustat Voxelotor

Dexmedetomidine

Niraparib ^IND

Bupivacaine extended release ^IND Fasinumab Lidocaïne Neridronic Acid SDN037 Tanezumab

Eryaspase (asparaginase)

Amantadine Istradefylline Levodopa / carbidopa

Abiraterone

Geïndiceerd met prednison of prednisolon voor: - de behandeling van nieuw gediagnosticeerde hoog-risico gemetastaseerde hormoongevoelige prostaatkanker (mHSPC) bij volwassen mannen, in combinatie met androgeendeprivatietherapie (ADT). - de behandeling van gemetastaseerde castratieresistente prostaatkanker (mCRPC) bij volwassen mannen die asymptomatisch of licht symptomatisch zijn na falen van androgeendeprivatietherapie en voor wie behandeling met chemotherapie nog niet klinisch geïndiceerd is. - de behandeling van mCRPC bij volwassen mannen bij wie de ziekte progressief was tijdens of na een chemotherapieschema op basis van docetaxel. ^G Geïndiceerd met prednison of prednisolon voor: - de behandeling van nieuw gediagnosticeerde hoog-risico gemetastaseerde hormoongevoelige prostaatkanker (mHSPC) bij volwassen mannen, in combinatie met androgeendeprivatietherapie (ADT); - de behandeling van gemetastaseerde castratieresistente prostaatkanker (mCRPC) bij volwassen mannen die asymptomatisch of licht symptomatisch zijn na falen van androgeendeprivatietherapie en voor wie behandeling met chemotherapie nog niet klinisch geïndiceerd is; - de behandeling van mCRPC bij volwassen mannen bij wie de ziekte progressief was tijdens of na een chemotherapieschema op basis van docetaxel. ^G

DCVAC

Darolutamide

Nubeqa is indicated for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. Adult men with metastatic hormone senstive prostate cancer (mHSPC) in combination with docetaxel en ADT. ^IND

Degarelix ^IND Enzalutamide ^IND Gozetotide Lutetium (177lu) vipivotide tetraxetan Masitinib Niraparib / abiraterone Olaparib ^IND Pembrolizumab ^IND Relugolix pembrolizumab ^IND

Anifrolumab Cyclobenzaprine hydrochloride Risankizumab ^IND Sarilumab ^IND Secukinumab ^IND

Tofacitinib

Tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive or negative polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have responded inadequately to previous therapy with DMARDs. Tofacitinib can be given in combination with methotrexate (MTX) or as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. ^IND Extension of indication for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy. ^IND

Onasemnogene abeparvovec Risdiplam

Lumateperone

Cemiplimab ^IND Darleukin fibromun Lifileucel

Pembrolizumab

1L treatment with pembrolizumab for advanced melanoma, in combination with lenvatinib. ^IND Extension of indication to include the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, Stage IIC or stage III melanoma and to include the treatment of adolescents aged 12 years and older with advanced melanoma for Keytruda ^IND

Relatlimab Seviprotimut-L Tavokinogene telseplasmid

Abrocitinib Beremagene geperpavec Berkenschorsextract Bimekizumab Crisaborole Deucravacitinib Difelikefalin Lebrikizumab Ligelizumab Regenerative Skin Tissue Risankizumab ^IND Ruxolitinib Secukinumab ^IND Spesolimab

Tapinarof

Adult Plaque Psoriasis Atopische dermatitis

Tirbanibulin Tralokinumab Upadacitinib ^IND

Daridorexant JZP-258 Natriumoxybaat controlled release Pitolisant

Inolimomab Motixafortide Narsoplimab Omidubicel Remestemcel-L Ruxolitinib ^IND Tabelecleucel Tisagenlecleucel-T ^IND autologous anti-CD19-transduced CD3+ cells

Avapritinib Nivolumab ^IND Ripretinib Rivoceranib Trastuzumab deruxtecan ^IND Zolbetuximab

Cabozantinib ^IND

Selpercatinib

Patients With RET-Mutant Medullary Thyroid Cancer. Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

Olopatadine / mometasone

Baloxavir marboxil Bizalimogene ralaplasmid Bulevirtide Doravirine / lamivudine / tenofovirdisoproxil ^IND Elbasvir / grazoprevir ^IND Glecaprevir / pibrentasvir ^IND Lonafarnib ^IND Maribavir Nirsevimab Sofosbuvir / velpatasvir / voxilaprevi ^IND Tecovirimat sofosbuvir / velpatasvir ^IND

Published on 7 December 2021

ADHD

ALL

Dasatinib

ALS

AML / MDS

Aggressive non-Hodgkin’s lymphoma

Antithrombotic medications

Asthma

Bacterial infections

Delamanid

Imipenem / cilastatin / relebactam

Bladder cancer

Bowel diseases

Brain cancer

Breast cancer

Atezolizumab

Pembrolizumab

Trastuzumab deruxtecan

CLL

Acalabrutinib

Ibrutinib

CML

COPD

COVID-19

Cardiovascular diseases

Cervical cancer

Colon cancer

Cystic fibrosis

Elexacaftor / tezacaftor / ivacaftor

Dementia

Depression

Esketamine

Diabetes

Exenatide

Duchenne

Epilepsy

Fenfluramine

Eye disorders

Ranibizumab

Fungal infections

Posaconazol

HIV

Head and neck cancer

Headache

Hemostasis promoting medication

Indolent non-Hodgkin’s lymphoma

Infectious diseases other

Kidney cancer

Pembrolizumab

Lipid-lowering medications

Liver cancer

Durvalumab

Liver diseases

Maralixibat

Lung cancer

Atezolizumab

Cemiplimab

Durvalumab

Lung diseases other

Mepolizumab

Lung other

Mesothelioma

Metabolic diseases

Multiple Myeloma

Belantamab mafodotin

Daratumumab

Isatuximab

Selinexor

Multiple sclerosis

Dimethyl fumarate

Teriflunomide

Muscular diseases other

Myeloproliferative disorders

Neuroendocrine cancer

Neurological disorders other

Oncology other

Lenvatinib

Nivolumab

Pembrolizumab